The study is divided into different phases. In the first phase, the study will test different doses of ONA-255 to find the lowest dose that has a biological effect and the highest dose that people can tolerate without serious side effects. In the next phase, the study will focus on finding the best dose to use for future studies in people with hormone receptor-positive, HER2-negative breast cancer and possibly in people with metastatic gastric or gastroesophageal junction cancer. In the final phase, the study will look at how many people respond to treatment with ONA-255 at the recommended dose. Throughout the study, doctors will monitor participants closely with physical examinations, blood tests, and imaging scans to check how the cancer is responding and to watch for any side effects.

The study will also collect blood samples to measure how the body processes ONA-255 and how long it stays in the body. Tissue samples from the cancer may be collected to study markers like FGFR4, HER2, and genetic changes such as ESR1, PIK3CA, TP53, and RB1 mutations to better understand how the treatment works. Some participants may also have their response measured using RECIST criteria, which is a standard way of measuring tumor size changes. The study may use placebo in some cases. Doctors will track how long the treatment works, how long people live without their cancer getting worse, and overall survival.

The main purpose is to determine if adding intraperitoneal paclitaxel to standard treatment helps patients live longer. During the study, patients will be randomly assigned to receive either the combination of intraperitoneal paclitaxel with standard therapy or standard therapy alone. The treatment period may continue for up to 60 months, depending on how well patients respond to the therapy.

Throughout the study, doctors will monitor patients’ overall health, measure how well the treatment is working, and track any side effects that may occur. They will also assess patients’ quality of life during and after treatment using specialized questionnaires. Some patients may later become eligible for surgery if their condition improves significantly with treatment.

The study involves people whose tumors test negative for a protein called HER2 but positive for two other proteins called CLDN18.2 and PD-L1. During the study, participants will receive either zolbetuximab or a placebo along with pembrolizumab and chemotherapy through intravenous infusions. Some chemotherapy medications will be given as tablets to take by mouth.

Researchers will track how long participants live, whether their cancer grows or spreads, and how their tumors respond to treatment. They will also monitor participants for any side effects from the treatment combination. The study will check blood samples to measure drug levels and test for the body’s immune response to the medications.

The purpose of the study is to determine if it is possible to safely give irinotecan directly into the abdominal cavity while patients are receiving their regular cancer treatment. The study will last approximately 18 months for each participant. During this time, patients will receive multiple treatment cycles combining intraperitoneal irinotecan with their standard cancer therapy.

The medication being tested, irinotecan, belongs to a group of drugs called DNA topoisomerase I inhibitors, which work by interfering with cancer cell growth. The treatment will be given at doses up to 75 milligrams per day, with a maximum total dose of 600 milligrams over the course of treatment. Researchers will monitor how well patients tolerate the treatment and track their progress throughout the study period.

Participants in the study will receive the treatment M9140 through an intravenous infusion, which means the medication is given directly into a vein. The study will be conducted in multiple phases, starting with a Phase 1b/2 trial, which is designed to assess the safety and effectiveness of the treatment. The study will monitor how the cancer responds to the treatment and will also keep track of any side effects experienced by participants. The trial will continue over several years to gather comprehensive data on the treatment’s impact.

Throughout the study, researchers will evaluate various outcomes, such as the number of participants who experience a reduction in cancer size, the duration of this response, and the overall control of the disease. They will also measure the time it takes for the treatment to start working and how long participants remain free from cancer progression. Additionally, the study will look at the levels of M9140 in the blood and whether participants develop any antibodies against the drug. This information will help determine the potential of M9140 as a treatment option for Advanced Gastric Cancer.

The purpose of the study is to determine how well these treatments work in patients who have not received prior treatment for their advanced cancer. Participants will receive their treatment through an intravenous injection, which means the medication is given directly into a vein. The study will last for a period of up to 60 weeks, during which participants will be monitored regularly to assess the progress of their cancer and any side effects they may experience.

Throughout the study, participants will undergo various assessments, including imaging tests like MRI or CT scans, to evaluate the size and spread of the cancer. The trial aims to provide valuable information on the potential benefits of the new treatment combination, which could lead to improved outcomes for patients with this type of cancer. Participants will be closely monitored by healthcare professionals to ensure their safety and well-being during the trial.

The purpose of the study is to evaluate how well the new combination works as a first-line treatment for patients with this type of cancer. Participants in the study will be randomly assigned to receive either the new combination or the standard treatment. The study is designed to be double-blinded, meaning neither the participants nor the researchers will know who is receiving which treatment. This helps ensure the results are unbiased. The study will take place over a period of time, with regular assessments to monitor the progress and health of the participants.

Throughout the study, researchers will focus on key outcomes such as progression-free survival, which measures how long patients live without the cancer getting worse, and overall survival, which measures how long patients live overall. The study will also look at the safety of the treatments and any side effects that may occur. By the end of the study, the goal is to determine if the new treatment combination offers a better option for patients with this type of cancer.

The purpose of the study is to evaluate how effective Dostarlimab is in treating this type of cancer. Participants in the study will receive the drug and will be monitored over a period of time to see how their cancer responds. The study will look at whether the cancer stops growing or shrinks, and whether patients can avoid surgery to remove the tumor. The study will also assess the safety of the drug and any side effects that may occur.

Participants will undergo regular check-ups, including medical tests and scans, to track their progress. The study aims to determine if Dostarlimab can help patients live longer without their cancer getting worse. This research is important for understanding new ways to treat gastric adenocarcinoma and potentially improve outcomes for patients with this condition.

The study is divided into two parts. In the first part, participants will receive DS-3939a to assess its safety and how well it is tolerated by the body. In the second part, the study will continue to evaluate safety and also measure the treatment’s effectiveness at a recommended dose. This will involve looking at how the cancer responds to the treatment, which is known as the objective response rate. Participants may have different types of advanced cancers, including those of the lung, breast, ovary, and pancreas, among others.

Throughout the study, participants will be closely monitored for any side effects or changes in their health. This includes regular check-ups, laboratory tests, and imaging studies to track the progress of the treatment. The study aims to gather important information that could lead to new treatment options for people with advanced solid tumors. Some participants may receive a placebo, which is a substance with no active medication, to help compare the effects of DS-3939a.